FilingReader Intelligence
Salubris reports profit growth, highlights innovation, shareholder returns
March 31, 2025 at 08:23 AM UTC•By FilingReader AI
Shenzhen Salubris Pharmaceuticals (SZSE:002294) reported a strong performance in its 2024 annual report, marked by significant investment in R&D and a commitment to shareholder returns. The company's board has proposed a cash dividend of CNY 5.00 per 10 shares, totaling CNY 557.41 million, demonstrating a focus on rewarding investors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2024 Annual Audit ReportMarch 28, 2025 at 12:52 PM UTC
Announcement on the merger of subsidiary Xintai Medical and its joint-stock companyMarch 28, 2025 at 12:52 PM UTC
Announcement on the 2024 Profit Distribution PlanMarch 28, 2025 at 12:52 PM UTC
Announcement on using idle funds to invest in financial productsMarch 24, 2025 at 12:19 PM UTC
Announcement on the use of part of the idle raised funds for cash managementMarch 24, 2025 at 12:19 PM UTC
SZSE:002294•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Shenzhen Salubris Pharmaceuticals publishes news
Free account required • Unsubscribe anytime